A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Acute Leukemias and Related Disorders

Inclusion Criteria:

- Men or women ≥ 18 years old

- Part 1 - Dose Escalation only: Pathologically documented, definitively diagnosed,
leukemia or related disorder that has failed standard treatment, for which no
standard therapy is available. Patients with myelodysplasia (MDS), chronic
myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), acute lymphocytic
leukemia (ALL), and chronic myelogenous leukemia (CML) are eligible for Part 1 of
this study Part 2 - Dose Expansion only: Pathologically documented, definitively
diagnosed, acute myeloid leukemia that has failed standard treatment, for which no
standard therapy is available.

- Must consent to undergo bone marrow biopsies per schedule of assessments

Exclusion Criteria:

- White blood cell greater than 20,000 uL

- History of or active central nervous system leukemia

- Prior allogeneic bone marrow transplant

- Subject will not be available for protocol-required study visits or procedures

Other Inclusion/ Exclusion Criteria may apply to qualify for enrollment